Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market to Reach USD 3.37 Billion by 2036 at 4.5% CAGR Across the 7MM | DelveInsight

DelveInsight's "ALK NSCLC Market Insights, Epidemiology and Market Forecast - 2036" report delivers an in-depth understanding of the ALK NSCLC, historical and forecasted epidemiology, as well as the ALK NSCLC market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market Report @ https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market Report
• In April 2026, Xcovery Holdings announced an agreement with EVERSANA to support and expand the US commercial launch of Ensartinib (ENSACOVE).
• In April 2026, Nuvalent announced the submission of an NDA for the ALKOVE-1 study of neladalkib to the US FDA.
• In April 2026, Nuvalent announced that pivotal data for neladalkib from the global ALKOVE-1 Phase I/II clinical trial, along with preliminary data for ALKAZAR, would be presented at the 2026 ASCO Annual Meeting.
• In April 2026, TRIANA Biomedicines announced that one oral and two poster presentations on TRI-611 would be presented at the AACR Annual Meeting 2026.
• In March 2026, TRIANA Biomedicines announced that the US FDA granted Fast Track designation to TRI-611 for the treatment of ALK+ NSCLC.
• In March 2026, TRIANA Biomedicines announced that the first patient had been dosed in a Phase I/II clinical trial evaluating TRI-611 in ALK-positive NSCLC patients.
• In January 2026, TRIANA Biomedicines announced a research collaboration with Johnson & Johnson to advance discovery of molecular glue targets in oncology.
• The ALK NSCLC market size in the 7MM was found to be approximately USD 2,050 million in 2025 and is projected to reach approximately USD 3,370 million by 2036, growing at a CAGR of approximately 4.5% during the forecast period (2026-2036).
• Among the 7MM, the US accounted for the largest ALK NSCLC market size, at approximately USD 1,280 million in 2025.
• Among the 7MM, the US accounted for the highest number of incident cases of ALK NSCLC, with approximately 10,000 cases in 2025.
• NSCLC shows a higher incidence in males, accounting for more than 55% of cases compared to females.
• Among age groups, the 65+ years category accounted for the highest age-specific cases, at more than 65% of total cases in 2025.
• Among EU4 and the UK, Germany accounted for the highest incident cases of ALK NSCLC, followed by the UK, with the least cases in Spain.
• The ALK NSCLC Companies include Roche, Genentech, Xcovery Holdings, Pfizer, Nuvalent, TRIANA Biomedicines, Astellas Pharma Global Development, and others.
• Promising ALK NSCLC Therapies include Neladalkib (NVL-655), TRI-611, and Gilteritinib, among others.

Get a Free sample for the Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer?
ALK-positive NSCLC is a genetically defined subset of lung cancer characterized by rearrangements in the ALK gene, most commonly the EML4-ALK fusion, which drive uncontrolled tumor growth. It is most commonly seen in younger patients, non-smokers, or light smokers with adenocarcinoma histology. This subtype is highly responsive to targeted therapies, which have transformed prognosis compared to conventional chemotherapy, and it often shows a tendency for early spread to the CNS, making brain-penetrant therapies especially important. Diagnosis relies on molecular testing to identify ALK gene rearrangements, using techniques such as immunohistochemistry, fluorescence in situ hybridization, or next-generation sequencing, with NGS increasingly preferred. Imaging studies, including brain MRI, are also commonly performed given the high incidence of CNS metastases.

Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Epidemiology Segmentation in the 7MM
• Total Incident Cases of NSCLC
• Gender-specific Incident Cases of NSCLC
• Age-specific Incident Cases of NSCLC
• Stage-specific Incident Cases of NSCLC
• Treated Cases of ALK NSCLC

Download the report to understand which factors are driving Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer epidemiology trends @ https://www.delveinsight.com/report-store/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Approved Therapies
• Alectinib (ALECENSA): Genentech and Roche
Alectinib is a highly selective, CNS-active, oral medicine for patients with ALK-positive NSCLC. It is a TKI that targets ALK fusion proteins, preventing signalling within cancer cells to inhibit their growth and survival. It is approved in over 80 countries as a first-line treatment for advanced ALK-positive NSCLC, and in over 90 countries for patients whose disease has worsened after, or who could not tolerate, crizotinib. Approval was based on the Phase III ALINA study, which showed alectinib reduced the risk of disease recurrence or death by 76% in ALK-positive early-stage resected NSCLC.

• Ensartinib (ENSACOVE): Xcovery Holdings
Ensartinib is a next-generation, small-molecule ALK TKI designed to selectively inhibit ALK-driven tumor growth while maintaining activity against several resistance mutations that limit earlier-generation therapies. Xcovery Holdings retains development and commercialization rights outside China, while Betta Pharmaceuticals, as majority owner of Xcovery, holds commercial rights in China. Ensartinib has demonstrated strong efficacy in both systemic and CNS disease.
Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Pipeline Analysis

• Neladalkib (NVL-655): Nuvalent
Neladalkib is an investigational, brain-penetrant, ALK-selective inhibitor designed to remain active in tumors resistant to first-, second-, and third-generation ALK inhibitors, including those with single or compound treatment-emergent ALK mutations such as G1202R. It has received Breakthrough Therapy Designation and Orphan Drug Designation from the US FDA.

• TRI-611: TRIANA Biomedicines
TRI-611 is a novel oral, small-molecule therapy designed to target and degrade ALK fusion proteins. It is a potent, brain-penetrant molecular glue degrader that brings ALK and cereblon together through a unique binding mechanism independent of the kinase active site.

Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Companies
Roche, Genentech, Xcovery Holdings, Pfizer, Nuvalent, TRIANA Biomedicines, Astellas Pharma Global Development, and others

Discover more about therapies set to grab major Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer market share @ https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market Outlook
The ALK-positive NSCLC treatment landscape has advanced significantly with the introduction of ALK tyrosine kinase inhibitors (TKIs). Alectinib remains the preferred first-line therapy because of its high efficacy, strong CNS activity, and favorable safety profile, while lorlatinib addresses resistance mutations with enhanced intracranial efficacy. Emerging therapies such as neladalkib and TRI-611 target resistance mechanisms, and gilteritinib is under investigation. Despite multiple first-line options, treatment selection remains challenging, with crizotinib still recommended in several regions, including Japan.

Scope of the Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Base Year: 2026
• Forecast Period: 2026-2036
• Coverage: 7MM (US, EU4 [Germany, France, Italy, Spain], UK, Japan)
• ALK NSCLC Companies: Roche, Genentech, Xcovery Holdings, Pfizer, Nuvalent, TRIANA Biomedicines, Astellas Pharma Global Development, and others
• ALK NSCLC Therapies: Alectinib (ALECENSA), Ensartinib (ENSACOVE), Lorlatinib (LORBRENA), Neladalkib (NVL-655), TRI-611, Gilteritinib, and others
• ALK NSCLC Therapeutic Assessment: ALK NSCLC current marketed and emerging therapies
• ALK NSCLC Market Dynamics: ALK NSCLC market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• ALK NSCLC Unmet Needs, KOL's views, Analyst's views, ALK NSCLC Market Access and Reimbursement

To know more about Anaplastic Lymphoma Kinase Non Small Cell Lung Cancer companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/anaplastic-lymphoma-kinase-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Methodology of ALK NSCLC
6. ALK NSCLC Market Overview at a Glance
7. Disease Background and Overview of ALK NSCLC
8. Epidemiology and Patient Population of ALK NSCLC
9. Patient Journey of ALK NSCLC
10. Marketed Therapies
11. Emerging Therapies
12. ALK NSCLC: Seven Major Market Analysis
13. Unmet Needs of ALK NSCLC
14. SWOT Analysis of ALK NSCLC
15. KOL Views of ALK NSCLC
16. Market Access and Reimbursement of ALK NSCLC
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.